Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Yu-Fei He
Blocking Programmed Death-1 Ligand-Pd-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine
Journal of Immunology
Allergy
Immunology
Related publications
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
Frontiers in Oncology
Cancer Research
Oncology
Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
Journal of Cancer
Oncology
2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer
Open Forum Infectious Diseases
Oncology
Neurology
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)
American Journal of Surgical Pathology
Anatomy
Forensic Medicine
Pathology
Surgery
PD-1 Receptor (PDCD1; PD-1; CD279); Programmed Cell Death 1 Ligand 1 (CD274 Molecule; PD-L1; B7-H1)
Science-Business eXchange
Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management
Therapeutic Advances in Medical Oncology
Oncology
Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers
British Journal of Cancer
Cancer Research
Oncology
The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort
Oncotarget
Oncology
Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
